Study Purpose: We are researching if an investigational medication, elranatamab, can help manage relapsed refractory multiple myeloma, a type of blood cancer, after other treatments have been used.

Study Details: Participants will take the investigational medication for up to 6 months. The study involves regular visits to the research site and monitoring for signs of disease progression or side effects. The investigational medication helps the body's immune system fight the cancer by targeting and killing myeloma cells. This study is open-label, meaning both doctors and participants know what treatment is being given.

Eligibility: You must be 18 or older with a history of relapsed refractory multiple myeloma after receiving a treatment called idecabtagene vicleucel. Participants must have good overall health, especially heart and liver function, and not be pregnant or breastfeeding.

• Duration: Up to 6 months of treatment, with additional follow-up if needed.
• Participant Count: Around 32 people will join this study.
• Criteria: Participants should have received multiple lines of prior treatments and meet specific health requirements.